Modified TBF Regimen as Conditioning Regimen Prior to Allogeneic Hematopoietic Cell Transplantation for T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma：Phase II Study
Modified TBF Regimen as Conditioning Regimen Prior to Allogeneic Hematopoietic Cell Transplantation for T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma：Phase II Study is a PHASE2 clinical asset sponsored by First Affiliated Hospital of Zhejiang University in Cytarabine+Thiotepa + Fludarabine + Busulfan, T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma. SEO and diligence focus: cytarabine+thiotepa+ fludarabine + busulfan, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Indication: Cytarabine+Thiotepa + Fludarabine + Busulfan
Modality: small molecule
Target: cytarabine+thiotepa+ fludarabine + busulfan
Sponsor: First Affiliated Hospital of Zhejiang University
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 22, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: cytarabine+thiotepa+ fludarabine + busulfan
View original source fields
Condition raw: Cytarabine+Thiotepa + Fludarabine + Busulfan, T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Condition normalized: Cytarabine+Thiotepa + Fludarabine + Busulfan, T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Modality raw: small molecule
Modality normalized: small molecule
Target raw: cytarabine+thiotepa+ fludarabine + busulfan
Target normalized: cytarabine+thiotepa+ fludarabine + busulfan